Research programme: benzimidazole nucleoside antivirals - University of Michigan
Alternative Names: BDCRB; TCRBLatest Information Update: 27 Apr 2007
At a glance
- Originator GlaxoSmithKline; University of Michigan
- Developer GlaxoSmithKline
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 10 Jun 2005 Preclinical trials in Cytomegalovirus infections treatment in USA (unspecified route)
- 30 Nov 2000 Discontinued - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
- 30 Nov 2000 Discontinued-Preclinical for Cytomegalovirus infections in United Kingdom (Unknown route)